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Ascitic fluid concentrations of fibronectin and 
cholesterol: comparison of differential diagnostic 
value with the conventional protein determination 
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Departments of Medicine II and 1lll, Klinikum Gros-
shadern, University of Munich, Munich, Federal Re-
public of Germany 
ABSTRACT - Ascitic fluid concentrations of fibronectin, cholesterol and protein were 
determined in 95 patients: 38 with cirrhosis of the liver, 10 with miscellaneous nonma-
lignant diseases, 43 with peritoneal carcinomatosis and 4 with liver metastases or 
hepatocellular Carcinoma. Fibronectin, cholesterol and protein at discrimination values 
of 7.5 mg/100 ml, 45 mg/100 ml and 3.0 g/100 ml, respectively, separated patients with 
peritoneal carcinomatosis from patients with cirrhosis with an efficiency of 94%, 90% 
and 85%, respectively. Thus, ascitic fluid determinations of fibronectin and cholesterol 
offer good discrimination of cirrhotic ascites from ascites related to peritoneal carci-
nomatosis, superior to the conventional protein determination. However, the failure 
of all parameters to distinguish ascites caused by miscellaneous nonmalignant diseases 
from malignancy-related ascites underscores the importance of highly specific methods 
to confirm a suspected diagnosis of malignancy-related ascites. 
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The presence of ascites can be related to malignant 
or nonmalignant diseases; the differentiation be-
tween these two conditions is of considerable clin-
ical significance for further diagnostic and thera-
peutic procedures. Ascitic fluid itself has been 
examined for parameters which might allow for 
the differential diagnosis. Cytological examin-
ation of ascitic fluid has proven rather insensitive 
with detection of malignant cells in only 40% to 
70% of malignancy-related ascites (1, 2). There-
fore, other parameters of ascitic fluid have been 
investigated for their differential diagnostic value, 
such as the most widely used total protein concen-
tration. In non-selected patients the diagnostic 
efficiency of the concentration of ascitic fluid total 
protein (3, 4), lactic dehydrogenase (5), carcino-
embryonic antigen (6, 7) or Fibrinogen degrada-
tion products (8) and oF the serum-ascites albumin 
concentration diFFerence (9) was Found to be be-
low 90%. Recently, an eFFiciency above 90% was 
reported For concentrations oF fibronectin (10) 
and cholesterol (11, 12). 
The present study was perFormed to compare 
these two seemingly superior parameters in the 
diFFerentiation oF malignancy-rekted ascites From 
nonmalignant ascites and to evaiuate their useFul-
ness, compared to total protein concentration in 
ascitic fluid. 
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Patients and methods 
Patients 
A total o f 95 patients with ascites was prospectively 
studied. Based on the ascites-related diseases, subjects 
were allocated to the following groups: 
Group 1 consisted of 38 patients (23 men, 15 women) 
with histologically proven liver cirrhosis from various 
causes (alcoholic in 18, posthepatitie in 11, biliary cir-
rhosis in 2, mixed or cryptogenic in 7 patients). Malig-
nancy was excluded in these patients by ultrasound, 
computed tomography or autopsy. 
Group 2 included 10 patients (6 men, 4 women) with 
misce l laneous causes of ascites related to nonmalignant 
diseases other than liver cirrhosis: congestive heart fail-
ure (2 pts.), ovarian Overstimulation by gonadotrophic 
hormones administered for infertility (2 pts.), portal vein 
thrombosis (2 pts.), pancreatitis (1 pt.), peritoneal tu-
bcrculosis (l pt.), systemic lupus erythematosus (1 pt.) 
and acute alcoholic hepatitis (1 pt.). 
Group 3 comprised 43 patients with ascites secondary 
to peritoneal carcinomatosis (10 men, 33 women). Clin-
ical diagnosis of peritoneal carcinomatosis was con-
firmed by peritoneoscopy, peritoneal biopsy, computed 
tomography or autopsy and/or a positive cytology of 
ascites. The underlying malignancies were: ovarian Carci-
n o m a (16 pts.), breast Cancer (6 pts.), Carcinoma of the 
stomach (5 pts.), of the pancreas (3 pts.), of the colon 
(2 pts.), of the kidney (2 pts.), leukemia (2 pts.), aden-
ocarcinoma of unknown origin (2 pts.), Carcinoma of 
the rectum (l pt.), of the bladder (1 pt.), Hodgkins 
disease (1 pt.), hepatocellular Carcinoma (1 pt.) and 
lymphosarcoma. 
Group 4 (3 men,l women) consisted of patients with 
malignant diseases and affection of the liver, but without 
evidence of peritoneal carcinomatosis: 1 patient with 
hepatocellular Carcinoma and cirrhosis of the liver, 3 
patients with liver metastases and Carcinoma of the 
breast, of the stomach and liposarcoma, respectively, as 
underlying diseases. 
Methods 
Cholesterol concentration was determined enzymatically 
with a commercial test kit (Boehringer, Mannheim, Fed-
eral Republic of Germany). Fibronectin was measured 
by means of laser nephelometry with a specific antiserum 
against human fibronectin, purchased from Boehringer, 
Mannheim, FRG. Total protein was determined by a 
commercial biuret method (Merck, Darmstadt, FRG). 
Results are given as mean and Standard deviation and 
as median and ränge, respectively. The Mann-Whitney 
test was used for comparing data between groups. Re-
ceiver-operator curves were calculated by Standard pro-
cedures (13). Applying cut-off limits for the determined 
parameters permitted Classification into four categories: 
true positive (a), true negative (b), false positive (c), and 
false negative (d). Sensitivity was calculated as (a/(a + 
d) x 100), specificity as (b/(b + c) x 100), positive predic-
tive value as (a/(a + c)), negative predictive value as (b/ 
(b + d)) and diagnostic efficiency as ((a + b)/(aH-b+c+ 
d)xl00)(13) . 
Results 
Ascitic fluid concentrations, ränge and median 
values, of cholesterol, fibronectin and protein are 
shown in Fig. 1. For all three parameters there 
was little overlap between patients with cirrhosis 
(Group 1) and patients with peritoneal carci-
nomatosis (Group 3). Whereas values of patients 
with nonmalignant diseases (Group 2) ranked be-
tween Groups 1 and 3, patients with liver metasta-
ses or hepatocellular Carcinoma (Group 4 ) exhibit-
ed ascitic fluid concentrations in the ränge of pa-
tients with cirrhosis. Mean values and Standard 
deviation as well as median values and ränge of 
the ascitic fluid concentrations of cholesterol, fi-
bronectin and protein are displayed in Table 1. 
In contrast to cholesterol and fibronectin, mean 
ascitic fluid protein concentration in patients with 
miscellaneous nonmalignant diseases (Group 2) 
was not significantly different from that in pa-
tients with peritoneal carcinomatosis (Group 3). 
When patients with malignancy-related ascites 
(Groups 3 and 4 ) and those with nonmalignant 
ascites (Groups 1 and 2) were considered together, 
the difference of ascitic fluid concentrations was 
more marked for cholesterol and for fibronectin 
than for protein (Table 1). The correlation of asci-
tic fluid concentrations of cholesterol and fi-
bronectin tended to be slightly superior to those 
of either parameter with ascitic protein concen-
tration (Table 2). 
As illustrated by the receiver-operator curves 
(Fig. 2a), differential diagnostic efficiency of chol-
esterol and fibronectin was superior to that of 
protein in separating patients with cirrhosis from 
patients with peritoneal carcinomatosis. Inclusion 
of patients with miscellaneous nonmalignant dis-
eases and of patients with liver metastases or he-
patocellular Carcinoma resulted in a decrease of 
differential diagnostic efficiency, particularly for 
protein concentration (Fig. 2b). 
This Observation was confirmed by the calcu-
lation of sensitivity, specificity, positive and nega-
tive predictive values and diagnostic efficiency 
(Table 3). Fibronectin, cholesterol and protein at 
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Fig. 1 ( a - c ) . Scattergram distribution of 
ascitic fluid concentrations of cholesterol 
(a), fibronectin (b) and total protein (c) 
in 38 patients with liver cirrhosis (Group 
1), 10 patients with miscellaneous nonma-
lignant diseases (Group 2), 43 patients 
with peritoneal carcinomatosis (Group 3) 
and 4 patients with liver metastases or 
hepatocellular Carcinoma (Group 4). 
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Table 1 
Ascitic fluid concentrations of cholesterol, fibronectin and protein 
Group 1 Group 2 Group 3 Group 4 Groups 1 + 2 Groups 3 + 4 
n = 38 10 43 4 48 47 
C h o l e s t e r o l (mg/100 m l ) 
Mean ± SD 19.7 ±17.2 46.8 + 21.3 85.1 ±30.1 28.8 ±11.4 25.4 ±21.0 80.3 ±33.4 
Median 16,6^ 44.9acf 8 0 0 a b d e 33 3 c f I9.2cf 79.8abdc 
Range 0.9-64.0 17.1-82.3 28.2-157.6 11.9-36.7 0.9-82.3 11.9-157.6 
F i b r o n e c t i n (mg/100 m l ) 
Mean 3.1 ±2.9 9.1 ±4.4 17.8±8.9 5.1+2.4 4.4 ±4.1 16.7 + 9 3 
Median 2.0bcf g 9 a c f 1 6 4 a b d e 5.3cf 2.8cf j 6 j a b d c 
Range 0.6-13.4 2.1-15.6 2.4-12.7 2.0-7.7 0.6-15.6 2.0-42.7 
Total p r o t e i n (g/100 m l ) 
Mean 1.6 ±1.3 3.7±0.8 4.0 ±0.9 2.0 ±0.7 2.0+1.5 3.8+1.1 
Median l.lbcf 3.5ad 4 0 a d e 2 2 b c f 1.6cf 4 0 a d c 
Range 0.2-5.4 2.7-5.4 1.7-5.6 1.1-2.6 0.2-5.4 1.1-5.6 
SigniFicant (p < 0.05) difference to aGroup 1 (liver cirrhosis), bGroup 2 (miscellaneous nonmalignant disease), cGroup 
3 (peritoneal carcinomatosis), dGroup 4 (liver metastases or hepatocellular Carcinoma), cGroups 1 +2 , fGroups 3 + 
4. 
discrimination values of 7.5 mg/100 ml, 45 mg/ 
100 ml and 3.0 mg/100 ml, respectively, separated 
patients with peritoneal carcinomatosis from pa-
tients with cirrhosis with an efficiency of 94%, 
90% and 85%, respectively. Inclusion of patients 
with miscellaneous nonmalignant diseases, liver 
metastases or hepatocellular Carcinoma reduced 
differential diagnostic efficiencies of the three in-
vestigated parameters to 85%, 82% and 74%, 
respectively. 
Discussion 
Stimulated by recent observations on the excellent 
differential diagnostic qualities of ascitic fluid 
concentrations of fibronectin and cholesterol (10, 
11), these parameters were prospectively evalu-
ated in the present study in 95 patients in compari-
son with the routine protein determination. In 81 
patients with liver cirrhosis (n = 38) or peritoneal 
carcinomatosis (n = 43), an excellent differential 
diagnostic efficiency of 94% for cholesterol and 
of 90% for fibronectin was found. Total protein 
concentration had an efficiency of 85% only. In-
clusion of patients with miscellaneous nonmalig-
nant diseases (n = 10) and with hepatic metastases 
or hepatocellular Carcinoma without peritoneal 
carcinomatosis (n = 4), however, reduced diag-
nostic accuracy by about 10% to 85%, 82% and 
74% for cholesterol, fibronectin and protein, re-
spectively. Thus, determination of cholesterol and 
fibronectin offer about the same differential diag-
nostic power, superior to protein determination. 
The mechanisms behind this Observation remain 
to be elucidated; possibly alterations of transper-
itoneal diffusion may play a role (12). 
Table 2 
Correlation of ascitic fluid concentrations of cholesterol, fibronectin and total protein 
Groups 1 + 2 
n = 48 
Groups 3 + 4 
n = 47 
Groups 1-4 
n = 95 
Cholesterol-fibronectin r = 0.77 0.61 0.80 
Cholesterol-protein r = 0.72 0.60 0.76 
Fibronectin-protein r = 0.74 0.55 0.71 
r: correlation coefficient. All correlations have a p-value below 0.001. Groups I (liver cirrhosis, n = 38) and 2 
(miscellaneous nonmalignant ascites, n = 10) comprise nonmalignant ascites, Groups 3 (peritoneal carcinomatosis, 
n = 43) and 4 (hepatic metastases and hepatocellular Carcinoma, n = 4) comprise malignancy-related ascites. 
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Sensitivity (%) Sensitivity (%) 
Fig. 2 ( a , b ) . Receiver-operator characteristics (ROC), displaying sensitivity and specificity at various discrimination 
levels for cholesterol, fibronectin and protein. As differential diagnostic efficiency improves, the curve approaches 
the left upper corner (100% sensitivity and 100% specificity) of the illustration. a: ROC for a total of 81 patients, 
including 38 patients with liver cirrhosis and 43 patients with peritoneal carcinomatosis. b: ROC for a total of 95 
patients, comprising 81 patients with cirrhosis or peritoneal carcinomatosis, 10 patients with miscellaneous nonmalig-
nant diseases and 4 patients with hepatic metastases or hepatocellular Carcinoma. 
There were two limitations which precluded any 
of the investigated parameters from providing a 
complete Separation of malignancy-related from 
nonmalignant ascites: malignancy-related ascites 
without peritoneal carcinomatosis could not be 
separated from nonmalignant ascites by any of 
the parameters in this study. This finding confirms 
observations by ourselves (12) as well as by others 
(14) and underscores that investigation of ascitic 
fluid cannot provide Information other than the 
usually negative cytological examination in these 
patients. This may explain the rather low ( < 80%) 
differential diagnostic efficiency of fibronectin, 
observed in a study comparing 18 patients with 
malignancy-related ascites, most of them without 
peritoneal carcinomatosis, to 30 patients with 
chronic liver disease (15). Furthermore, increased 
ascitic fluid concentrations of protein or any other 
Parameter are not totally specific for malignancy-
related ascites (16, 17); therefore a combination 
Table 3 
Diagnostic value of cholesterol, fibronectin and total protein in ascitic fluid 
Cholesterol Fibronectin Total protein 
Discrimination value 
Groups 
45 mg/100 ml 7.5 mg/100 ml 3.0 g/100 ml 
1,3 1-4 1,3 1-4 1,3 1-4 
Sensitivity (%) 95 87 91 85 81 75 
Specificity (%) 92 83 89 80 89 73 
Efficiency (%) 94 85 90 82 85 74 
Pos. predictivity (%) 93 84 91 80 90 73 
Neg. predictivity (%) 95 87 89 84 81 74 
Diagnostic value of ascitic fluid cholesterol, fibronectin and total protein for separating ascites related to liver 
cirrhosis (Group 1, n = 38) from ascites related to peritoneal carcinomatosis (Group 3, n = 43) and for Separation 
of nonmalignant ascites (Group 1 and Group 2: n = 10, miscellaneous nonmalignant ascites) from malignancy-
related ascites (Group 3 and Group 4: n = 4, hepatic metastases and hepatocellular Carcinoma). 
FIBRONECTIN AND CHOLESTEROL IN ASCITES 157 
of these parameters might increase sensitivity but 
will invariably decrease specificity and hence will 
not improve diagnostic discrimination. In the 
present study, protein concentrations in ascites 
due to nonmalignant diseases other than cirrhosis 
were more often in the ränge of concentrations 
found in peritoneal carcinomatosis than fibronec-
tin or cholesterol concentrations, resulting in re-
duced specificity, particularly of protein. The fail-
ure of all investigated parameters to distinguish 
ascites caused by miscellaneous nonmalignant dis-
eases from malignancy-related ascites underscores 
the importance of highly specific methods to con-
firm a suspected diagnosis of malignancy-related 
ascites. 
However, in patient populations with a high 
percentage of cirrhotic and peritoneal carcinoma-
tosis ascites and a consequently small fraction 
of both noncirrhotic, nonmalignant ascites and 
malignancy-related ascites without peritoneal car-
cinomatosis, cholesterol and fibronectin determi-
nation offer useful differential diagnostic qualit-
ies, superior to those of protein determination. 
Since cholesterol can be determined more easily 
and cheaply than fibronectin, it may be recom-
mended as a first-line routine parameter of ascitic 
fluid investigation. 
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